摘要
目的评价异基因外周血干细胞移植(Allo-PBSCT)治疗白血病的疗效及移植相关并发症。方法回顾分析9例白血病患者行同胞供者Allo-PBSCT治疗。预处理方案为改良马利兰加环磷酰胺(Bu/CY);预防移植物抗宿主病(GVHD)采用环孢素A(CSA)加短程甲氨蝶呤(MTX)和霉酚酸酯(MMF)。结果 8例患者均获得造血重建,白细胞植活的中位时间为15(13～16)d;1例未植入。出现GVHD 7例,肝静脉闭塞病(HVOD)3例,出血性膀胱炎(HC)1例。中位随访时间为13(0～30)个月6例存活,其中5例为无病存活,3例死亡。结论 Allo-PBSCT治疗白血病有效,移植相关并发症可接受。
Objective To explore the clinical effects and complications of allogeneic peripheral blood stem cell transplantation on the treatment of Leukemia. Methods The clinical data of 9 patients undergoing allo-PBSCT were analyzed retrospectively. The improved busulfan and cyclophosphamide （Bu/CY） were used as condition pretreatment regimen. Cyclosporine A （CsA） and short-course methotrexate（MTX） and mycophenlate mofetil （MMF） were administered to prevent the graft versus host disease （GVHD）. Result 8 patients were engrafted successfully, the median time of reconstruct was 15 （ 13 - 16） days; One patient was not engrafted. Seven patients suffered GVHD and 3 patients suffered hepatic veno-occlusive disease （HVOD） and 1 patient suffered hemorrhagic cystitis （HC）. With a median follow-up of 13 （0 -30）months, six patients （66.7%）were alive, among them,5 patients （55.6%） were disease-free and 3 patients died. Conclusions Allo-PBSCT is effective in the treatment of leukemia and the complications of transplantation are still acceptable.
出处
《内科》
2011年第4期303-306,共4页
Internal Medicine
关键词
白血病
外周血干细胞移植
异基因
并发症
Leukemia
Peripheral blood stem cell transplantation
Allogeneic
Complication
